Mangalam Drugs And Organics Ltd Stock Analysis

BSE: 532637 | NSE: MANGALAM | Pharmaceuticals & Drugs | Small Cap

BSE Share Price 09-Jun-2023 17:59
105.15 -0.45 (-0.43%)

DeciZen - Make an Informed Decision on Mangalam Drugs&Org.

Overall Rating
M-Cap below 500cr. High Risk from low Liquidity

1. Quality

2. Valuation

Fair

3. Price Trend

Semi Strong

Mangalam Drugs&Org. Price Chart

P/E Ratio ( SA) :
131.61
Market Cap :
167.2 Cr.
52-wk low :
95
52-wk high :
172.7
Bole Toh?

1. Is Mangalam Drugs And Organics Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Mangalam Drugs And Organics Ltd is a average quality company.

2. Is Mangalam Drugs And Organics Ltd undervalued or overvalued?

The key valuation ratios of Mangalam Drugs And Organics Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Mangalam Drugs And Organics Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Mangalam Drugs And Organics Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Mangalam Drugs&Org.:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Mangalam Drugs And Organics Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
ROCE % -4.9%3.8%12.9%19.8%22%17.1%-1.2%9.9%19.8%12.9%-
Value Creation Index -1.4-0.7-0.10.40.60.2-1.1-0.30.4-0.1-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 125123221295303279228282385451370
YoY Gr. Rt. %--2.2%80%33.8%2.7%-7.8%-18.5%24.1%36.3%17.3%-
Adj EPS -9-2.34.711.214.512.3-5.15.217.712.40.8
YoY Gr. Rt. %-NANA138.9%29.3%-15.4%-141.6%NA240.5%-29.9%-
BVPS (₹) 19.917.622.336.954.265.660.465.782.695.196
Adj Net Profit -11.8-3.16.216.22319.4-8.18.22819.61
Cash Flow from Ops. -0.77.51421.842.824.621.730.627.625.7-
Debt/CF from Ops. -110.410.35.62.71.52.82.91.62.33.1-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 15.3%8.3%25.6%17.3%
Adj EPS NA-3.1%NA-29.9%
BVPS 1911.916.315.1
Share Price 37.3% 0% 16% -26.8%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
Return on Equity % -36.8-12.423.635.531.220.5-8.18.223.813.90.8
Op. Profit Mgn % -3.57.99.312.815.516.84.38.415.110.96.9
Net Profit Mgn % -9.4-2.52.85.57.67-3.62.97.34.30.3
Debt to Equity 2.83.32.71.10.80.70.70.50.50.50.1
Working Cap Days 175188152130114130162136126131206
Cash Conv. Cycle 121123675658628347486941

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 25.61%

Return on Equity has declined versus last 3 years average to 0.80%

Net Profit has been subdued in last 3 years 0.00%

Sales growth is not so good in last 4 quarters at -15.37%

Latest Financials - Mangalam Drugs And Organics Ltd.

Standalone Consolidated
TTM EPS (₹) 0.8 -
TTM Sales (₹ Cr.) 370 -
BVPS (₹.) 96 -
Reserves (₹ Cr.) 136 -
P/BV 1.10 -
PE 131.61 -
From the Market
52 Week Low / High (₹) 95.00 / 172.65
All Time Low / High (₹) 3.43 / 441.50
Market Cap (₹ Cr.) 167
Equity (₹ Cr.) 15.8
Face Value (₹) 10
Industry PE 38.1

Management X-Ray of Mangalam Drugs&Org. :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *33.5733.5733.5711.5916.8819.9816.9716.2216.6520.93
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Mangalam Drugs&Org.

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)

News

Mangalam Drugs And Organics Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Mangalam Drugs&Org. on 09-Jun-2023 17:59 is : 105.2.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 09-Jun-2023 17:59 the market cap of Mangalam Drugs&Org. stood at ₹ 167.2.
The latest PE ratio of Mangalam Drugs&Org. as of 09-Jun-2023 17:59 is 131.6.
The latest PB ratio of Mangalam Drugs&Org. as of 09-Jun-2023 17:59 is 1.10
The 52-week high of Mangalam Drugs&Org. is ₹ 172.7 and the 52-week low is ₹ 95.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Mangalam Drugs&Org. is ₹ 370.2 ( Cr.) .

About Mangalam Drugs And Organics Ltd

Mangalam Drugs & Organics Limited (Mangalam) is a part of the MangalamGroup promoted by Dhoot family in 1972 as Advent Pharma PrivateLimited with a view to set up a plant for manufacture of organic andinorganic chemicals. Mangalam Drugs & Organics commmenced its business in 1977.

The company manufactures chemicals such as API perfumery, disperse dye intermediates, bulk drugs and bulk drugs intermediates at VAPI-Gujarat State. It has a multi-product manufacturing facility and a in-house Research and Development (R&D) Base.

The Company has a diversified product range having synergies in operations and substantial economies of scale. It is amongst the top three manufacturers in India in almost all the products that it manufactures.

Today Mangalam Drugs & Organics enjoys a very strong brand name in the domestic market. It has over two decades of experience in the industry with a very wide and satisfied customer base.

The company has a state of art multi-product manufacturing facilitiesat Vapi in Gujarat and Sangamner in Maharashtra for production of bulkdrugs perfumery chemicals inorganic chemicals and disperse dyesintermediaries with a strong in-house Research and Development base.

Product range of the company includes:

Active Pharma Ingredients (API)

  • Anti Malarial
  • Analgesic / Anti Inflammatory
  • Diuretic
  • Anti Hypertensive
  • Anti Convulsant

API Under Development

  • Intermediates
  • Antiurolithic

Prefumery / Specialty Chemicals

  • Phenyl Ethyl Alcohol
  • Phenyl Ethyl Methyl Ether
  • Phenyl Ethyl Acetate

Disperse Dye Intermediates

  • Meta Nitro Aniline (Mna)(99-09-2)
  • Meta Amino Propionilide (MAP)
  • Meta Amino Acetanilide (MAA) (162-28-3)
  • Para Amino Acetanilide (PAA) 122-80-5)
  • Para Amino Propionilide (PAP) (59690-89-0)
  • N-Cyano Ethyl Aniline (1075-76-9)
  • N,N-BIS (2-Hydroxy Ethyl) Meta Chloro Aniline (Mangalam-1) (92-00-2)
  • N,N-BIS (2-Acetoxy Ethyl) Meta Chloro Aniline (Mangalam -1A) (26692-46-6) etc.

Achievements/ recognition:

  • Awarded the ISO 9001:2000 Management System Certificate from DNV for Design Development, Manufacture and supply of Bulk Drugs, and Dyes Intermediates.
  • Received the WHO GMP Certificate for its Bulk Drug manufacturing Plant
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now